Top Industry Leaders in the Urethritis Market
Latest Urethritis Companies Update
November 2023: Roche's new immunoassay, Elecsys® HBeAg quant, can detect the hepatitis B e antigen (HBeAg) in human blood and plasma and provide a quantitative and qualitative reading of its presence, was unveiled on November 2023. With the release of this test, patients will be able to establish the presence or absence of hepatitis B (HBV), the severity of their infection, and the efficacy of their treatment with only one set of laboratory findings and clinical data. In nations that recognize the CE Mark, it is compatible with the cobas® e analyzers. Worldwide, healthcare systems and individuals alike bear the brunt of hepatitis B virus (HBV), the most prevalent form of the virus that affects people of all ages.
the European launch of ResistancePlus® MG FleXible was announced by SpeeDx Pty, Ltd. This test is the first of its kind to identify Mycoplasma genitalium (Mgen), a sexually transmitted infection (STI), as well as indicators linked to azithromycin resistance. With Cepheid's FleXible Cartridge program for the GeneXpert System, this test can only be distributed by Cepheid. Premature birth, infertility, and pelvic inflammatory disease are among reproductive health issues associated with Mgen, which can also cause urethritis, cervicitis, endometritis, and other symptoms.2,3 All Mgen testing guidelines agree that only symptomatic persons should be tested, citing the difficulties of increasing antibiotic resistance and the absence of conclusive evidence that asymptomatic infection causes long-term health consequences.
List of Urethritis Key companies in the market
- F. Hoffmann-La Roche AG
- GlaxoSmithKline
- AbbVie
- Johnson & Johnson
- Merck & Co.
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Bayer AG
- AstraZeneca plc